The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
Open accessAbstract
Background: In comparison to warfarin, non–vitamin K antagonist oral anticoagulants ( NOAC s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for ongoing monitoring. We sought to evaluate whether these advantages translate to improved adherence and whether adherence is associated with improved outcomes in patients with atrial fibrillation. Methods and Results: We performed a retrospective cohort analysis by using a large US commercial insurance database to identify 64 661 patients with atrial fibrillation who initiated warfarin, dabigatran, rivaroxaban, or apixaban treatment between November 1, 2010, and December 31, 2014. During a median of 1.1 y of follow‐up, 47.5% of NOAC patients had a proportion of days covered of ≥80%, compared with 40.2% in warfarin patients ( P <0.001). Patients with CHA 2 DS 2 ‐ VAS c (risk based on the presence of congestive heart failure, hypertension age 65–74 y, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category) score ≥4 were at increased risk of stroke when they were not taking anticoagulation ≥1 month versus <1 week (1–3 months: hazard ratio [ HR ] 1.96, 3–6 months: HR 2.64, ≥6 months: HR 3.66; all P <0.001). Patients with CHA 2 DS 2 ‐ VAS c score 2 or 3 were at increased risk of stroke when they were not taking anticoagulation ≥6 months ( HR 2.73, P <0.001). In these patients with CHA 2 DS 2 ‐ VAS c score ≥2, nonadherence was not associated with intracranial hemorrhage. Among patients with CHA 2 DS 2 ‐ VAS c score 0 or 1, time not taking anticoagulation was not associated with stroke, but not taking anticoagulation ≥3 months was associated with a significant reduction of bleeding. Conclusions: Adherence to anticoagulation is poor in practice and may be modestly improved with NOAC s. Adherence to therapy appears to be most important in patients with CHA 2 DS 2 ‐ VAS c score ≥2, whereas the benefits of anticoagulation may not outweigh the harms in patients with CHA 2 DS 2 ‐ VAS c score 0 or 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Hylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061
Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., & Singer, D. E. (2003) · JAMA · doi:10.1001/jama.290.20.2685 · Cited by 703
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects
Lavallée, P. C., Meseguer, E., Abboud, H., Cabrejo, L., Olivot, J.-M., Simon, O., Mazighi, M., Nifle, C., Niclot, P., Lapergue, B., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70248-x · Cited by 668
Validating Administrative Data in Stroke Research
Tirschwell, D. L., & Longstreth, W. T. (2002) · Stroke · doi:10.1161/01.str.0000032240.28636.bd · Cited by 658
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Optum Labs: Building A Novel Node In The Learning Health Care System
Wallace, P. J., Shah, N. D., Dennen, T., Bleicher, P. A., & Crown, W. H. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0038 · Cited by 445
Self-citationPerioperative atrial fibrillation and the long-term risk of ischemic stroke
Gialdini, G., Nearing, K., Bhave, P. D., Bonuccelli, U., Iadecola, C., Healey, J. S., & Kamel, H. (2014) · JAMA · doi:10.1001/jama.2014.9143 · Cited by 355
Abraham, N. S., Singh, S., Alexander, G. C., Heien, H., Haas, L. R., Crown, W., & Shah, N. D. (2015) · BMJ · doi:10.1136/bmj.h1857 · Cited by 347
Self-citationSherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Spyropoulos, A. C., Hankey, G. J., Singer, D. E., Nessel, C. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005754 · Cited by 267
Chao, T.-F., Liu, C.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Tuan, T.-C., Chen, T.-J., Lip, G. Y. H., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.046 · Cited by 258 · cited 1×
“Estimates of baseline untreated stroke risk in this low-risk population vary in the literature.(13,46,47) We found that adherence to anticoagulation was not associated with a significant reduction in stroke in patients with CHA2DS2-VASc score 0 or 1, suggesting that the stroke risk is not easily modified in low-risk p…”
BackgroundShore, S., Carey, E. P., Turakhia, M. P., Jackevicius, C. A., Cunningham, F., Pilote, L., Bradley, S. M., Maddox, T. M., Grunwald, G. K., Barón, A. E., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.023 · Cited by 226
National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial Fibrillation
Fang, M. C., Stafford, R. S., Ruskin, J. N., & Singer, D. E. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.55 · Cited by 224
Friberg, L., Skeppholm, M., & Terént, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.10.052 · Cited by 207
Patel, M. R., Hellkamp, A. S., Lokhnygina, Y., Piccini, J. P., Zhang, Z., Mohanty, S., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.057 · Cited by 203
Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Singer, D. E. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.937680 · Cited by 185
Held, C., Hylek, E. M., Alexander, J. H., Hanna, M., Lopes, R. D., Wojdyla, D. M., Thomas, L., Al-Khalidi, H., Alings, M., Xavier, D., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu463 · Cited by 173
Vrijens, B., & Heidbuchel, H. (2015) · Europace · doi:10.1093/europace/euu311 · Cited by 172
Lip, G. Y. H., Skjøth, F., Rasmussen, L. H., & Larsen, T. B. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.044 · Cited by 171 · cited 1×
“Estimates of baseline untreated stroke risk in this low-risk population vary in the literature.(13,46,47) We found that adherence to anticoagulation was not associated with a significant reduction in stroke in patients with CHA2DS2-VASc score 0 or 1, suggesting that the stroke risk is not easily modified in low-risk p…”
BackgroundChang, H., Zhou, M., Tang, W., Alexander, G. C., & Singh, S. (2015) · BMJ · doi:10.1136/bmj.h1585 · Cited by 163
Self-citationZalesak, M., Siu, K., Francis, K. M., Chen, Y. X., Alvrtsyan, H., Rao, Y., Walker, D. R., Sander, S. D., Miyasato, G., Matchar, D. B., et al. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000192 · Cited by 163
Gorst‐Rasmussen, A., Skjøth, F., Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Lane, D. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12845 · Cited by 149
Jun, M., James, M. T., Manns, B. J., Quinn, R. R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W. C., Ma, Z., Hemmelgarn, B. R., et al. (2015) · BMJ · doi:10.1136/bmj.h246 · Cited by 143
Andrade, J. G., Krahn, A. D., Skanes, A. C., Purdham, D. M., Ciaccia, A., & Connors, S. P. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.09.023 · Cited by 112
Palareti, G., Legnani, C., Guazzaloca, G., Frascaro, M., Grauso, F., Rosa, F. D., Fortunato, G., & COCCHERI, S. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648843 · Cited by 104
Adherence to anticoagulant treatment with dabigatran in a real‐world setting
Schulman, S., Shortt, B., Robinson, M., & Eikelboom, J. W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12241 · Cited by 99
Noseworthy, P. A., Yao, X., Deshmukh, A. J., Houten, H. V., Sangaralingham, L. R., Siontis, K. C., Piccini, J. P., Asirvatham, S. J., Friedman, P. A., Packer, D. L., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002597 · Cited by 94
Self-citationShields, A. M., & Lip, G. Y. H. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12360 · Cited by 76
Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey
Holt, T., Hunter, T. D., Gunnarsson, C., Khan, N., Cload, P., & Lip, G. Y. H. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x656856 · Cited by 72
Noseworthy, P. A., Kapa, S., Deshmukh, A. J., Madhavan, M., Houten, H. V., Haas, L. R., Mulpuru, S. K., McLeod, C. J., Asirvatham, S. J., Friedman, P. A., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.02.020 · Cited by 61
Self-citationFauchier, L., Lecoq, C., Clémenty, N., Bernard, A. B., Angoulvant, D., Ivanés, F., Babuty, D., & Lip, G. Y. H. (2015) · CHEST Journal · doi:10.1378/chest.15-1622 · Cited by 59
Cutler, T., Chuang, A., Huynh, T. D., Witt, R. G., Branch, J. M., Pon, T. K., & White, R. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.10.1028 · Cited by 40
Comparison of three medication adherence measures in patients taking warfarin
Wang, Y., Kong, M. C., & Ko, Y. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0872-5 · Cited by 33
The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?
Renda, G., & Caterina, R. D. (2013) · Vascular Pharmacology · doi:10.1016/j.vph.2013.07.003 · Cited by 28
Withdrawal of warfarin after deep vein thrombosis
Ascani, A., Iorio, A., & Agnelli, G. (1999) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199907000-00011 · Cited by 23
Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation
Singer, D. E., & Ezekowitz, M. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.11.013 · Cited by 15
The hazards of interrupting anticoagulation therapy in atrial fibrillation
Hohnloser, S. H., & Eikelboom, J. W. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs032 · Cited by 11
The Predicament of Comparative Effectiveness Research Using Observational Data
Curtis, J. P., & Krumholz, H. M. (2015) · Annals of Internal Medicine · doi:10.7326/m15-2490 · Cited by 9
Cited by
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Andrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 492
Self-citationYao, X., Shah, N. D., Sangaralingham, L. R., Gersh, B. J., & Noseworthy, P. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.600 · Cited by 467
Self-citationTomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Metadata
- Authors
- Yao, X., Abraham, N. S., Alexander, G. C., Crown, W., Montori, V. M., Sangaralingham, L. R., Gersh, B. J., Shah, N. D., & Noseworthy, P. A.
- Venue
- Journal of the American Heart Association
- Published
- 2016-02-23
- Volume
- 5
- Issue
- 2
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2281540926
- Cited by
- 452
- References
- 50
- FWCI
- 52.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.